| Metric | Q2 FY27 | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue from operations | 56.0 | 103.8 | 90.3 |
| Other income | 7.7 | 8.7 | 9.4 |
| Total income | 63.8 | 112.5 | 99.7 |
| Profit before exceptional items & tax | -32.8 | 43.2 | 32.6 |
| Exceptional items | -68.3 | 0.0 | 0.0 |
| Profit before tax | -101.1 | 43.2 | 32.6 |
| Net profit | -77.5 | 32.2 | 24.2 |
| Operating margin | -158.5% | 38.4% | 32.7% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Revenue, year on year | -38.00% |
|---|---|
| Operating profit, year on year | -274.60% |
| Operating profit, quarter on quarter | -217.40% |
BSE results filing, NSE: NOVARTIND. Figures extracted from the filing.
Evonile Pharma Ltd: key numbers
- Share price
- ₹1,719.85
- Market cap
- ₹4,246 Cr
- Revenue (annual)
- ₹354.3 Cr
- Net profit (annual)
- ₹93.18 Cr
- P/E (TTM)
- 43.4×Sector 41.3×
- Promoter holding
- 70.68%+0.00% QoQ
- FII holding
- 1.21%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Evonile Pharma Ltd
All →Evonile Pharma Results Update
Evonile Pharma reported Q2 FY27 revenue of ₹56.1 crore and an EBITDA loss of ₹31.8 crore. H1 FY27 profit after tax was a loss of ₹45.3 crore.
Evonile Pharma Investor Presentation: Key Takeaways
Q2 FY27 revenue fell 38% YoY to ₹56.1 cr, with a ₹77.5 cr net loss including ₹68 cr exceptional items. Transition from single-customer model to independent distribution continues.
Novartis India Board Meeting Date
Evonile Pharma will hold a board meeting on November 4, 2026 to approve the rights issue letter of offer. BSE granted in-principle approval for the rights issue.
Novartis India Management Change
Evonile Pharma (formerly Novartis India) appointed Mr. Gagan Sharma as President – Specialty Business and Senior Management Personnel effective October 26, 2026. The filing is a Regulation 30 senior management appointment intimation.
Novartis India Other Announcement
Novartis India Ltd has filed its quarterly shareholding pattern for the period ended September 30, 2026, as required under SEBI regulations. This is a routine periodic disclosure.
Novartis India Annual General Meeting
Evonile Pharma (fka Novartis India) issued a postal ballot notice for shareholder votes on ESOP 2026 grant to the MD & CEO and creation of charge on assets. E-voting runs 14 Oct–12 Nov 2026.